Carlyle Bets on Essential Pharma in €900 Million Financing Deal
- AlpInvest and Sixth Street are part of recapitalization deal
- Essential Pharma is looking for further acquisitions
This article is for subscribers only.
Private equity firms Carlyle Group Inc.’s AlpInvest and Sixth Street are backing Essential Pharma as part of a €900 million ($945 million) recapitalization of the drugmaker.
AlpInvest is leading the refinancing of Essential Pharma, which has been owned by Swiss-based investment firm Gyrus Capital since 2019. Sixth Street is providing €300 million of structured equity and growth debt, the drugmaker said in a statement.